Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Roland Heinig"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 2, Pp 199-211 (2022)
Abstract Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist that recently demonstrated its efficacy to delay chronic kidney disease (CKD) progression and reduce cardiovascular events in patients with CKD and type 2 diabetes
Externí odkaz:
https://doaj.org/article/5f67bf9fd1c741cc83b6cb4ab6b7a925
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 47:803-815
In vitro and in vivo studies were performed with the novel, selective, nonsteroidal mineralocorticoid receptor antagonist finerenone to assess the relevance of inhibitory effects on the transporters breast cancer resistance protein (BCRP), organic an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5866d7ef59f66b6e9832b3295802bd6c
https://doi.org/10.1007/s13318-022-00794-5
https://doi.org/10.1007/s13318-022-00794-5
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
Purpose: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, and RAF). This first-in-man, phase I dose–escalation study assessed the safety, pharmacokinetic, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c80f812b75f509f0f95d8d4511a9475
https://doi.org/10.1158/1078-0432.c.6520397
https://doi.org/10.1158/1078-0432.c.6520397
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
PDF file, 41KB.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::014dc1095ba0e6f04ade76edca1b1c5c
https://doi.org/10.1158/1078-0432.22445144.v1
https://doi.org/10.1158/1078-0432.22445144.v1
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
PDF file, 52KB, Adverse events that led to permanent treatment discontinuation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0012c977ee3864af62502dce8eb60d34
https://doi.org/10.1158/1078-0432.22445141.v1
https://doi.org/10.1158/1078-0432.22445141.v1
Autor:
Olaf Christensen, Oliver Boix, Roland Heinig, Jörn Krätzschmar, Clemens Unger, Ulrike Fasol, Martin Büchert, Susanne Hedbom, Simone Steinbild, Annette Frost, Klaus Mross
PDF file, 71KB, Best responses (maximum reduction in sum of longest diameter of target lesions from baseline) in individual patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18b2a7d07a67c24c91c0ee12990bc4bd
https://doi.org/10.1158/1078-0432.22445147
https://doi.org/10.1158/1078-0432.22445147
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 47:549-559
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist that reduces the risk of adverse kidney and cardiovascular outcomes in patients with chronic kidney disease associated with type 2 diabetes mellitus. Clinical phase I studies with fin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d80bd91159fd0c185053ffb18a07bd40
https://doi.org/10.1007/s13318-022-00770-z
https://doi.org/10.1007/s13318-022-00770-z
Autor:
Dirk Garmann, Bart Ploeger, Henk-Jan Drenth, Thomas Eissing, Peter Kolkhof, Nelleke Snelder, Amer Joseph, Jörg Lippert, Roland Heinig
Publikováno v:
Clinical Pharmacokinetics
Background Finerenone (BAY 94-8862) is a potent non-steroidal, selective mineralocorticoid receptor antagonist being developed for the treatment of patients with type 2 diabetes and chronic kidney disease. Methods We present the population pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6c9208a9f324acf3ed71c94f0fdaccf
https://doi.org/10.1007/s40262-019-00820-x
https://doi.org/10.1007/s40262-019-00820-x
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 44:619-628
Finerenone (BAY 94-8862) is a selective, nonsteroidal mineralocorticoid receptor antagonist. The aim of this study was to assess the effect of mild or moderate hepatic impairment on the pharmacokinetics, safety and tolerability of finerenone. The stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a86ba5a18feb09e6fe8899fe9203918e
https://doi.org/10.1007/s13318-019-00547-x
https://doi.org/10.1007/s13318-019-00547-x
Publikováno v:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 1172
A straightforward and rapid high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay allowing the sensitive and selective quantitation of finerenone (BAY 94–8862) in lithium heparin human plasma is described. Finerenon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee71ba4d3d0ef8c8a289709cfe939cc
https://pubmed.ncbi.nlm.nih.gov/33770684
https://pubmed.ncbi.nlm.nih.gov/33770684